535 related articles for article (PubMed ID: 35251014)
1. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.
Wang Y; Chen R; Wa Y; Ding S; Yang Y; Liao J; Tong L; Xiao G
Front Immunol; 2022; 13():829451. PubMed ID: 35251014
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic.
Rios-Hoyo A; Arriola E
Front Immunol; 2023; 14():1221097. PubMed ID: 37876939
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
7. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis.
Tsakonas G; Ekman S; Koulouris A; Adderley H; Ackermann CJ; Califano R
Int J Cancer; 2023 Nov; 153(9):1556-1567. PubMed ID: 37334528
[TBL] [Abstract][Full Text] [Related]
9. Single-Cell Profiling Comparisons of Tumor Microenvironment between Primary Advanced Lung Adenocarcinomas and Brain Metastases and Machine Learning Algorithms in Predicting Immunotherapeutic Responses.
Wu Y; Kang K; Han C; Wang L; Wang Z; Zhao A
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671569
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
Wei Y; Xu Y; Wang M
Chin Med J (Engl); 2023 Jul; 136(13):1523-1531. PubMed ID: 37106555
[TBL] [Abstract][Full Text] [Related]
11. [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC].
Lan Q; Ji C; Yao Y
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):512-519. PubMed ID: 31451142
[TBL] [Abstract][Full Text] [Related]
12. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.
Zhao Y; Guo S; Deng J; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Wen Q; Li J; Xiao Z
Int J Biol Sci; 2022; 18(9):3845-3858. PubMed ID: 35813484
[TBL] [Abstract][Full Text] [Related]
13. Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.
Del Conte A; De Carlo E; Bertoli E; Stanzione B; Revelant A; Bertola M; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743275
[TBL] [Abstract][Full Text] [Related]
14. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.
Fan TW; Higashi RM; Song H; Daneshmandi S; Mahan AL; Purdom MS; Bocklage TJ; Pittman TA; He D; Wang C; Lane AN
Elife; 2021 Aug; 10():. PubMed ID: 34406120
[TBL] [Abstract][Full Text] [Related]
15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
16. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
20. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
